<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848066</url>
  </required_header>
  <id_info>
    <org_study_id>2015-07-146</org_study_id>
    <nct_id>NCT02848066</nct_id>
  </id_info>
  <brief_title>Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker</brief_title>
  <official_title>Open, Parallel, Single-Site Study to Evaluate Sensitivity and Specificity of Newly Defined Diagnosed-biomarker for Gastric Cancer Pts and Cancer-free Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate sensitivity and specificity of newly defined tumor
      biomarker with gastric cancer pts and cancer-free healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Measurements of specific glycosylation changes in serum haptoglobin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(Area Under the Curve)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of glycosylations</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">355</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Gastric Cancer patients</arm_group_label>
    <description>This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer-free healthy volunteers</arm_group_label>
    <description>This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample(10cc) collection</intervention_name>
    <description>In both groups, serum haptoglobins to be collected and analyzed</description>
    <arm_group_label>Gastric Cancer patients</arm_group_label>
    <arm_group_label>Cancer-free healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Arm1- Gastric cancer patient: 150 subjects Arm2- Cancer-free healthy volunteers : 203
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Arm1 (Gastric cancer patient)

          1. Inclusion Criteria:

               -  Male or female over 19 years

               -  Patients with histologically Gastric Cancer (included Gastroesphageal junction)

               -  Primary gastric cancer or/and metastatic gastric cancer.

               -  Understand and voluntarily sign an informed consent document prior to any study
                  related assessments/procedures are conducted

          2. Exclusion Criteria:

               -  Prior or present history of malignancies other than gastric cancer

               -  Any condition that confounds the ability to interpret data from the study under
                  the investigational confirmed.

        Arm2 (Cancer-free healthy volunteers)

          1. Inclusion Criteria:

               -  Male or female over 19 years

               -  Cancer-free status.

               -  Understand and voluntarily sign an informed consent document prior to any study
                  related assessments/procedures are conducted

          2. Exclusion Criteria:

               -  Prior or present history of malignancies (included gastric cancer)

               -  Any condition that confounds the ability to interpret data from the study under
                  the investigational confirmed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>sehoon Park</last_name>
    <email>sh1767.park@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunwoo Nam</last_name>
    <email>wsna.nam@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sehoon Park</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, Radich J, Anderson G, Hartwell L. The case for early detection. Nat Rev Cancer. 2003 Apr;3(4):243-52. Review.</citation>
    <PMID>12671663</PMID>
  </reference>
  <reference>
    <citation>Paik YK, Kim H, Lee EY, Kwon MS, Cho SY. Overview and introduction to clinical proteomics. Methods Mol Biol. 2008;428:1-31. Review.</citation>
    <PMID>18287765</PMID>
  </reference>
  <reference>
    <citation>Asazawa H, Kamada Y, Takeda Y, Takamatsu S, Shinzaki S, Kim Y, Nezu R, Kuzushita N, Mita E, Kato M, Miyoshi E. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development. Clin Chem Lab Med. 2015 Jan;53(1):95-102. doi: 10.1515/cclm-2014-0427.</citation>
    <PMID>25060348</PMID>
  </reference>
  <reference>
    <citation>Hoagland LF 4th, Campa MJ, Gottlin EB, Herndon JE 2nd, Patz EF Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007 Nov 15;110(10):2260-8.</citation>
    <PMID>17918261</PMID>
  </reference>
  <reference>
    <citation>Thompson S, Cantwell BM, Matta KL, Turner GA. Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer. Cancer Lett. 1992 Aug 14;65(2):115-21.</citation>
    <PMID>1511415</PMID>
  </reference>
  <reference>
    <citation>Park SY, Lee SH, Kawasaki N, Itoh S, Kang K, Hee Ryu S, Hashii N, Kim JM, Kim JY, Hoe Kim J. α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int J Cancer. 2012 May 15;130(10):2366-76. doi: 10.1002/ijc.26288. Epub 2011 Sep 22.</citation>
    <PMID>21780104</PMID>
  </reference>
  <reference>
    <citation>Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34. Review.</citation>
    <PMID>10580127</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

